Approval of Audited standalone Financial results alongwith Audited Report thereon for financial year 2025-26
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kimia Biosciences reported audited standalone results for FY2025-26 with revenue from operations at Rs 11,488.38 lakhs, down from Rs 11,892.08 lakhs in the previous year (approx 3.4% decline). Profit before tax stood at Rs 846.01 lakhs compared to Rs 1,363.42 lakhs in FY25, representing a significant decline. PAT for the year was Rs 743.37 lakhs versus Rs 961.24 lakhs in the prior year. Basic EPS declined to Rs 1.64 from Rs 2.04. Operating cash flow remained positive at Rs 1,084.40 lakhs. The auditor issued an unmodified opinion with no qualifications. The company has working capital limits of Rs 29.60 crores from Kotak Mahindra Bank with Rs 22.71 crores utilized as of March 31, 2026.
The decline in revenue and profitability is concerning for shareholders. However, the clean audit opinion and positive operating cash flows provide some comfort. The company redeemed preference share capital of Rs 8 crores during the year, indicating efforts to streamline capital structure.